FDA Clears Toshiba’s Latest Aquilion CT
The Aquilion Prime 80 features the AIDR 3D dose reduction software.
Toshiba America Medical Systems Inc. has received FDA clearance for the latest in its Aquilion CT product line, the Aquilion Prime 80 series, the company announced Monday.
The system, which features their Adaptive Iterative Dose Reduction 3D software, can generate 80 unique slices per rotation and is designed with in-field upgradeability to 160 slices, the company said.
The Aquilion Prime features a 0.5 mm detector, a 7.5 MHU large-capacity tube and 0.35 second scanning. The system also includes a 78 cm aperture gantry and a 660-pound patient-weight-capacity couch. In addition to the AIDR 3D software, the system comes with Nema XR 25 Dose Check Software which includes dose alert and notification features.
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.
